Cardiac amyloidosis is believed to be substantially underrecognized and underdiagnosed. There are two types of cardiac amyloidosis: light-chain (AL) and TTR amyloidosis. Recent advances in imaging technologies and more thorough genetic analyses have revealed that cardiac amyloidosis may be more common than previously believed. While treatments for amyloidosis have dramatically changed over the past decade resulting in extended survival, clinician awareness and understanding continues to be underdeveloped, including timely detection and prompt diagnosis causing delays in subsequent treatment.

Education is critical to disseminating information about the importance of amyloidosis screening in patients who are deemed at-risk for this condition. Cardiologists also require education regarding appropriate imaging studies and interpreting findings for cardiac amyloidosis to improve differential diagnosis and expedite referral and treatment.